Calithera’s Telaglenastat Doubles PFS In Proof-Of-Concept Study

The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.

Human kidney on scientific background. 3d illustration
• Source: Shutterstock

Calithera Biosciences Inc.’s telaglenastat (CB-839) has doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma (RCC) when used in combination with everolimus in the Phase II ENTRATA study, top-line data show.

This makes telaglenastat the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer. The drug is designed...

More from Clinical Trials

More from R&D